Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 816-832

  Newton, Herbert B ^a,b   Turowski, Robert C ^b   Stroup, Tammie J ^d   McCoy, Laura K ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d NONE

Author keywords

Benign; chemotherapy; Primary brain tumors: malignant

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOLACTOL; MUSTARD GAS DERIVATIVE; NATURAL PRODUCT; NIMUSTINE; NITROSOUREA DERIVATIVE; OMEPRAZOLE; PACLITAXEL; PLATINUM DERIVATIVE; PROCARBAZINE; RANITIDINE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

BLOOD TOXICITY; BRAIN TUMOR; CANCER CLASSIFICATION; GENE THERAPY; HEADACHE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEIZURE; STOMACH ULCER; STROKE; TREATMENT PLANNING;

EID: 0032791681     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18353     Document Type: Review

References (155)

1. Newton HB. Primary brain tumors: review of etiology, diagnosis, and treatment. Am Fam Physician 1994;49:787-97.
2. Black PM. Brain tumors. First of two parts. N Engl J Med 1991;324: 1471-6.
3. Lopes MBS, VandenBerg SR, Scheithauer BW. Histopathology, immunochemistry and ultrastructure of brain tumors. In: Kaye AH, Laws ER, eds. Brain tumors. Edinburgh: Churchill Livingstone, 1995:125-62.
4. Brem S, Rozental RM, Moskal JR. What is the etiology of human brain tumors? A report on the first Lebow conference. Cancer 1995;76:709-13.
5. Preston-Martin S. Epidemiology of primary brain tumors. Neurol Clin 1996;14:273-90.
6. Masters LY, Zimmerman RD. Imaging of supratentorial brain tumors in adults. Neuroimaging Clin North Am 1993;3:649-70.
7. Schwartz RB. Neuroradiology of brain tumors. Neurol Clin 1995;13: 723-56.
8. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-6.
9. 3 receptor antagonists. Support Care Cancer 1994;2: 286-92.
10. Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am 1987;71:303-11.
11. Grossman SA, Staats PS. Current management of pain in patients with cancer. Oncology 1994;8:93-107.
12. Breitbart W. Psycho-oncology: depression, anxiety, delerium. Semin Oncol 1994;21:754-69.
13. Ohnishi T, Sher PB, Posner JB, Shapiro WB. Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 1990;72:245-51.
14. Del Maestro RF, Megyesi JF, Farrell CL. Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 1990;17:177-83.
15. Mukwaya G. Immunosuppressive effects and infections associated with corticosteroid therapy. Pediatr Infect Dis J 1988;7:499-504.
16. Weissman DE, Dufer D, Vogel V, Abeloff DD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987;5:125-8.
17. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989;7:479-91.
18. Batchelor TT, Taylor LT, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997;48:1234-8.
19. Garnett WR, Garabedian-Ruffalo SM. Identification, diagnosis, and treatment of acid-related diseases in the elderly: implications for long-term care. Pharmacotherapy 1997;17:938-58.
20. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
21. Britton JW, So EL. Selection of antiepileptic drugs: a practical approach. Mayo Clin Proc 1996;71:778-86.
22. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334: 168-75.
23. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334:1583-90.
24. Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996; 46:985-91.
25. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67.
26. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:3-28.
27. Anderson N, Lokich JJ. Cancer chemotherapy and infusional scheduling. Oncology 1994;8:99-111.
28. Shibuya M, Ito S, MiwaT, Davis RL, Wilson CB, Hoshino T. Proliferative potential of brain tumors. Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleoloar organizer region counts. Cancer 1993;71:199-206.
29. Stewart DJ. Pros and cons of intra-arterial chemotherapy. Oncology 1989;3:20-6.
30. Gumerlock MK, Neuwelt EA. Principles of chemotherapy in brain neoplasia. In: Jellinger K, ed. Therapy of malignant brain tumors. New York: Springer Verlag, 1987:277-348.
31. Tomita T. Interstitial chemotherapy for brain tumors: review. J Neurooncol 1991;10:57-74.
32. Sipos EP, Brem H. New delivery systems for brain tumor therapy. Neurol Clin 1995;13:813-25.
33. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640-7.
34. Tamargo RJ, Myeseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-33.
35. Brem H, Tamargo RJ, Olivi A, Pinn M, Wharam M, Epstein J. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994;80: 283-90.
36. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;354:1008-12.
37. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-9.
38. Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, et al. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical Phase I trial in patients with malignant brain tumors. Cancer Treat Reports 1981;65:39-43.
39. Neuwelt EA, Kroll RA. Osmotic blood-brain barrier modification: increasing delivery of diagnostic and therapeutic agents to the brain. Methods Neurosci 1994;21:52-67.
40. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-82.
41. Gumerlock MK, Belshe BD, Madsen R, Watts C. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 1992; 12:33-46.
42. Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996;85:1056-65.
43. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
44. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988;68:1-17.
45. Kyritsis AP. Chemotherapy for malignant gliomas. Oncology 1993;7:93-100.
46. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology 1998;12:537-47.
47. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batzdorf U, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Reports 1983;67:121-32.
48. Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, VanGilder JC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
49. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
50. Vega F, Davila L, Chatellier G, Chiras J, Fauchon F, Cornu P, et al. Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy. J Neurooncol 1992;13:131-5.
51. Chauveinc L, Sola-Martinez MT, Martin-Duverneuil M, Mazeron JJ, Faillot T, Cornu P, et al. Intra arterial chemotherapy with ACNU and radiotherapy in inoperable malignant gliomas. J Neurooncol 1996;27:141-7.
52. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiol Oncol Biol Phys 1990;18:321-4.
53. Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990;40:1743-6.
54. Newton HB, Bromberg J, Junck L, Page MA, Greenberg HS. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neurooncol 1993;15:257-63.
55. Longee DC, Friedman HS, Albright RE, Burger PC, Oakes WJ, Moore JO, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990;72:583-8.
56. Spence AM, Berger MS, Livinston RB, Ali-Osman F, Griffin B. Phase II evaluation of high-dose cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neurooncol 1992; 12:187-91.
57. Mahaley MS, Hipp SW, Dropcho EJ, Bertsch L, Cush S, Tirey T, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989;70:371-8.
58. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a Phase II study. J Clin Oncol 1991;9:860-4.
59. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a Phase II study. J Clin Oncol 1992;10:1074-7.
60. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant gliomas. J Neurooncol 1996;27:149-55.
61. Elliot TE, Dinapoli RP, O'Fallon JR, Krook JE, Earle JD, Morton RF, et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. J Neurooncol 1997;33:239-50.
62. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol 1998; 38:59-68.
63. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981;55:749-56.
64. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997; 54:554-8.
65. Peterson K, Peleologos N, Forsyth P, Macdonald DR, Cairncross JG. Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996;85: 597-601.
66. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J Clin Oncol 1997;15:3427-32.
67. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992;76:741-5.
68. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-7.
69. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
70. Evans AE, Jenkin RDT, Sposto BSR, Ortega AE, Wilson CB, Wara W, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-82.
71. Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:433-40.
72. Friedman HS, Mahaley MS, Schold SC, Vick NA, Falletta JM, Bullard DE, et al. Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 1986;18:335-40.
73. Walker RW, Allen JC. Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 1988;6:62-6.
74. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987;5:459-63.
75. Levin VA, Edwards MSB, Gutin PH, Vestnys P, Fulton D, Seager M, et al. Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. J Neurosurg 1984;61:1063-8.
76. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
77. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90.
78. Cheng AL, Yen KH, Uen WC, Hung RL, Liu MY, Wang CH, et al. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma. A pilot study of the BOMES protocol. Cancer 1998;82:1946-51.
79. Coyle T, Baptista J, Winfield J, Clark K, Poiesz B, Kirshner J, et al. Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a Phase II study. J Clin Oncol 1990;8:2014-8.
80. Carpenter PA, White L, McCowage GB, Nayanar V, Toogood I, Shaw PJ, et al. A dose-intensive, cyclosphosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood. A report from the Australia and New Zealand Children's Cancer Study Group. Cancer 1997;80:489-96.
81. Newton HB, Newton CL. Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. J Neurooncol 1995;24:285-92.
82. Elliot TE, Buckner JC, Cascino TL, Levitt R, O'Fallon JR, Scheithauer BW. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neurooncol 1991;10:27-31.
83. Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglass E, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4:1253-61.
84. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
85. Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990;28:823-8.
86. Aronin PA, Mahaley MS, Rudnick SA, Dudka L, Donohue JF, Selker RG, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. An assessment of risk factors. N Engl J Med 1980; 303:183-8.
87. 1 mice and the effects of pre-treatment with procarbazine, phenobarbital, diphenylhydantoin, and methylprednisolone upon in vivo procarbazine activity. Cancer Chemother Pharmacol 1983;11:124-9.
88. Erickson JM, Tweedie DJ, Ducore JM, Prough RA. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 1989;49:127-33.
89. 6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989;70:573-7.
90. Maxwell MB. Reexamining the dietary restrictions with procarbazine (an MAOI). Cancer Nurs 1980;(Dec):451-7.
91. Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989;64:2420-3.
92. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-4.
93. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992;31:78-82.
94. Hellman RM, Calogero JA, Kaplan BM. VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors. J Neurooncol 1990;8:163-6.
95. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995;270: 1842-5.
96. Bertolone SJ, Baum ES, Krivit W, Hammond GD. A Phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neurooncol 1989;7:5-11.
97. Mosijczuk AD, Nigro MA, Thomas PRM, Burger PC, Krischer JP, Morantz RA, et al. Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. Cancer 1993;72: 2755-62.
98. Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, et al. Intracarotid infusion of cis-diamminedichloro-platinum in the treatment of recurrent malignant brain tumors. Cancer 1984;54:794-9.
99. Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T, et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 1992;10:452-8.
100. Newton HB, Page MA, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989;7:39-45.
101. Doz F, Berens ME, Dougherty DV, Rosenblum ML. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 1991; 11:27-35.
102. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized Phase II study. J Clin Oncol 1992;10:249-56.
103. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. A Phase II study. Cancer 1998;82: 355-61.
104. Follézou JY, Fauchon J, Chiras J. Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a Phase II study. Neoplasm 1989; 36:349-52.
105. Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37: 17-28.
106. Cascino TL, Veeder MH, Buckner JC, O'Fallon JR, Wiesenfeld M, Levitt R, et al. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. J Neurooncol 1996;30:243-6.
107. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9:679-93.
108. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-9.
109. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992;10:766-71.
110. Chu E, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy. Principles and practice. 2nd ed. Philadelphia: Lippincott-Raven, 1996:109-48.
111. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 1989;70:190-4.
112. Grant R, Naylor B, Junck L, Greenberg HS. Clinical outcome in aggressively treated meningeal gliomatosis. Neurology 1992;42:252-4.
113. Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin 1991;9:955-67.
114. van Maanen JMS, Retèl J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988;80: 1526-33.
115. Goldberg SL, Ahlgren JD. Recent clinical experience with infusional etoposide. J Infusion Chemo 1991;1:37-43.
116. Tirelli U, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, et al. Etoposide (VP-16-213) in malignant brain tumors: a Phase II study. J Clin Oncol 1984;2:432-7.
117. Buckner JC, Brown LD, Cascino TL, Gerstner JB, Krook JE, Westberg MW, et al. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol 1990;9:249-54.
118. Corden BJ, Strauss LC, Killmond T, Carson BS, Wharam MD, Kumar AJ, et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neurooncol 1991;11:57-63.
119. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
120. Kuhn JG. Pharmacology of irinotecan. Oncology 1998;12:39-42.
121. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994;34:171-4.
122. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC. et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996;78:527-31.
123. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516-25.
124. Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998;12:72-8.
125. Horváth IP, Csetényi J, Hindy I, Kerpel-Fronius S, Institoris L, Hegedüs L, et al. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man - II. Pharmacokinetics of DBD. Eur J Cancer Clin Oncol 1982;18:1211-9.
126. Áfra D, Kocsis B, Dobay J, Eckhardt S. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. J Neurosurg 1983;59:106-10.
127. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 1994;44:1479-83.
128. Hildebrand J, De Witte O, Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU, and procarbazine. J Neurooncol 1998;37:155-60.
129. Schrell UMH, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 1997;86:845-52.
130. Schrell UMH, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997;86:840-844.
131. Spitz IM, Bardin CW. Mefepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404-12.
132. Carroll RS, Glowacka D, Dashner K, Black PM. Progesterone receptor expression in meningiomas. Cancer Res 1993;53:1312-6.
133. Olson JJ, Beck DW, Schlechte J, Loh PM. Hormonal manipulation of meningiomas in vitro. J Neurosurg 1986;65:99-107.
134. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-6.
135. Friedman ZY. Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest 1998;16:391-6.
136. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990;50:7134-8.
137. Couldwell WT, Weiss MH. DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32:485-90.
138. Chang SM, Barker FG, Huhn SL, Nicholas MK, Page M, Rabbitt J, et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 1998;37:169-76.
139. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-14.
140. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, et al. Paclitaxel distribution in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995;87:1077-81.
141. Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC, Spence AM, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998;16:2188-94.
142. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996;14:2316-21.
143. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
144. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 1997;32:253-65.
145. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72.
146. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59:520-9.
147. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJS, Cavenee WK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 1997; 93:109-17.
148. Bernsen HJJA, Rijken PFJW, Peters H, Bakker H, van der Kogel AJ. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neurooncol 1998;38:51-7.
149. Fine HA, Loeffler JS, Kyritsis A, Wen P, Black PM, Levin VA, et al. A Phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas (abstract). Proc ASCO 1997;16:385a.
150. Freeman SM, Zwiebel JA. Gene therapy of cancer. Cancer Invest 1993; 11:676-88.
151. Zlokovic BV, Apuzzo MLJ. Cellular and molecular neurosurgery: pathways from concept to reality - part I: targets and concept approaches in gene therapy of the central nervous system. Neurosurgery 1997;40: 789-804.
152. Zlokovic BV, Apuzzo MLJ. Cellular and molecular neurosurgery: pathways from concept to reality - part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery 1997;40:805-13.
153. Barba D, Hardin J, Ray J, Gage FH. Tymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993;79:729-35.
154. Fueyo J, Gomez-Manzano C, Yung WKA, Liu TJ, Alemany R, Bruner JM, et al. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998;50:1307-15.
155. Rosenfeld MR, Meneses P, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG. Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology 1995;45:1533-9.